OraSure Technologies OSUR HIV — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by OraSure Technologies in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: OraSure Technologies’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about OraSure Technologies's hiv — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OraSure Technologies's HIV — net revenues?
- OraSure Technologies (OSUR) reported HIV — net revenues of $13.02M in Q1 2026.
- How has OraSure Technologies's HIV — net revenues changed year-over-year?
- OraSure Technologies's HIV — net revenues increased by 0.9% year-over-year, from $12.9M to $13.02M.
- What is the long-term trend for OraSure Technologies's HIV — net revenues?
- Over 4 years (2021 to 2025), OraSure Technologies's HIV — net revenues has grown at a 4.3% compound annual growth rate (CAGR), from $42.14M to $49.8M.
- What does HIV — net revenues mean?
- This metric represents the total gross sales generated from the sale of diagnostic tests and specimen collection devices specifically designed for the detection of HIV. It serves as a key indicator of the company's market penetration and demand within the infectious disease diagnostics sector. Monitoring these revenues helps investors assess the commercial performance and growth trajectory of the company's specialized HIV-related product portfolio.